Gilead Sciences, Inc.

NASDAQ:GILD   3:59:59 PM EDT
68.50
+0.69 (+1.02%)
: $68.73 +0.23 (+0.34%)
Products, Regulatory

U.S. Food And Drug Administration Approves New Formulation Of Epclusa

Published: 06/10/2021 21:15 GMT
Gilead Sciences, Inc. (GILD) - U.S. Food and Drug Administration Approves New Formulation of Epclusa®, Expanding Pediatric Indication to Treat Children Ages 3 and Older With Chronic Hepatitis C.
Gilead Sciences Inc - FDA Approval for Epclusa Includes Boxed Warning.
Gilead Sciences Inc - FDA Approved a NDA for Two Strengths of an Oral Pellet Formulation of Epclusa.